当前位置： SCI文献检索 > HIV CLINICAL TRIALS期刊下所有文献 > Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.

Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.

Abstract：

PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a questionnaire about clinical trials and met with a research assistant who discussed the purpose of clinical trials. After the educational intervention, participants completed a second questionnaire and responses from the two surveys were compared. RESULTS:115 patients were enrolled (56% had previously enrolled in a clinical trial; 50% of whom were currently enrolled in a trial); 92% would consider participating in a future clinical trial. Increased patient trust in the provider was associated with increased willingness to participate in a trial. After the intervention, 94% indicated that they would be willing to be contacted about a clinical trial for which they may be eligible and 85% preferred to be contacted by their primary physician. CONCLUSIONS:Patients' trust in their provider may predict willingness to participate in clinical trial. Providing HIV-infected patients and their providers with information about HIV clinical trials at the site where they receive care may increase participation rates in HIV clinical trials.

journal_name

HIV Clin Trials

journal_title

HIV clinical trials

authors

Volkmann ER,Claiborne D,Currier JS

doi

10.1310/hct1002-104

subject

Has Abstract

pub_date

2009-03-01 00:00:00

pages

104-9

issue

2

eissn

1528-4336

issn

1945-5771

pii

8VP563TG7R033760

journal_volume

10

pub_type

杂志文章

相关文献

HIV CLINICAL TRIALS文献大全
  • Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.

    abstract：PURPOSE:Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab. METHOD:We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnose...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct0803-132

    authors： Ezzat H,Filipenko D,Vickars L,Galbraith P,Li C,Murphy K,Montaner JS,Harris M,Hogg RS,Vercauteren S,Leger CS,Zypchen L,Leitch HA

    更新日期：2007-05-01 00:00:00

  • Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

    abstract：PURPOSE:Selecting the optimal treatment regimen for antiviral-naive patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), b...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/WT81-MEM4-5C4L-CHPK

    authors： Simpson KN,Luo MP,Chumney E,Sun E,Brun S,Ashraf T

    更新日期：2004-09-01 00:00:00

  • Missing scheduled visits in the outpatient clinic as a marker of short-term admissions and death.

    abstract：INTRODUCTION:It is not uncommon for patients with HIV infection to miss scheduled visits in outpatient clinics without justifying the failure to appear or reschedule the appointment. Few studies have assessed the impact of inconsistent follow-ups on resource use and disease outcomes in this patient population. OBJECTI...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1305-289

    authors： Colubi MM,Pérez-Elías MJ,Elías L,Pumares M,Muriel A,Zamora AM,Casado JL,Dronda F,López D,Moreno S,SEAD Study Group.

    更新日期：2012-09-01 00:00:00

  • Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls.

    abstract：BACKGROUND:Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adul...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1179/1528433614Z.0000000003

    authors： Ashby J,Foster C,Garvey L,Wan T,Allsop J,Paramesparan Y,Taylor-Robinson SD,Fidler S,Winston A

    更新日期：2015-03-01 00:00:00

  • Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.

    abstract：OBJECTIVES:ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r pati...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1310/hct1206-313

    authors： Fourie J,Flamm J,Rodriguez-French A,Kilby D,Domingo P,Lazzarin A,Ballesteros J,Sosa N,Van De Casteele T,DeMasi R,Spinosa-Guzman S,Lavreys L

    更新日期：2011-11-01 00:00:00

  • Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects.

    abstract：BACKGROUND:Unannounced home-based pill counts conducted in person or on the telephone are reliable and valid for monitoring medication adherence. However, expecting to have one's pills counted, organizing medications for pill counts, and increased attention from the person conducting the pill counts may have reactive e...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/hct1106-325

    authors： Kalichman SC,Amaral C,Swetsze C,Eaton L,Kalichman MO,Cherry C,Detorio M,Caliendo AM,Schinazi RF

    更新日期：2010-11-01 00:00:00

  • Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

    abstract：BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,多中心研究

    doi：10.1310/hct1401-10

    authors： Gutiérrez C,Hernández-Novoa B,Pérez-Elías MJ,Moreno AM,Holguín A,Dronda F,Casado JL,Moreno S

    更新日期：2013-01-01 00:00:00

  • Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy.

    abstract：PURPOSE:The outdated rules of older HIV genotypic resistance algorithms can affect virologic responses. This study was designed to determine how often these incorrect resistance interpretations affect analyses of long-term clinical trials, antiretroviral (ARV) choices, and HIV disease progression rates. METHOD:Baselin...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct0805-293

    authors： Desai S,Kyriakides T,Holodniy M,Al-Salman J,Griffith B,Kozal M

    更新日期：2007-09-01 00:00:00

  • Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.

    abstract：OBJECTIVE:To determine the prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain. DESIGN:Epidemiologic, cross-sectional, and non-interventional study between January and June 2008 in HIV-1-infected patients in Spain. METHODS:A total of 485 treatment-experienced patients from across Spainand wi...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1006-394

    authors： Moreno,Clotet,Sarría,Ortega,Leal,Rodriguez-Arrondo,Sánchez-de la Rosa,Allegro Study Group.

    更新日期：2009-11-01 00:00:00

  • Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.

    abstract：OBJECTIVES:Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-existing drug resistance. The current study examined the impact of pre-existing drug resistance mutatio...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1080/15284336.2015.1115585

    authors： Porter DP,Toma J,Tan Y,Solberg O,Cai S,Kulkarni R,Andreatta K,Lie Y,Chuck SK,Palella F,Miller MD,White KL

    更新日期：2016-02-01 00:00:00

  • Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

    abstract：OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1310/hct1403-81

    authors： Nelson MR,Elion RA,Cohen CJ,Mills A,Hodder SL,Segal-Maurer S,Bloch M,Garner W,Guyer B,Williams S,Chuck S,Vanveggel S,Deckx H,Stevens M

    更新日期：2013-05-01 00:00:00

  • Clinically stable treatment-experienced adults receiving tenofovir and didanosine.

    abstract：METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/0B0R-J1LP-KQPF-43HB

    authors： Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

    更新日期：2006-01-01 00:00:00

  • Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

    abstract：PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1310/RRX7-49ME-27V7-MWWV

    authors： MacGregor TR,Sabo JP,Norris SH,Johnson P,Galitz L,McCallister S

    更新日期：2004-11-01 00:00:00

  • Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes.

    abstract：BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/X618-KWKJ-WCTQ-LQ2L

    authors： Gallego O,d Mendoza C,Labarga P,Altisent C,González J,García-Alcalde I,Valer L,Valencia E,Soriano V

    更新日期：2003-11-01 00:00:00

  • Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

    abstract：PURPOSE:The objectives of this study were to determine the prevalence of osteopenia and the factors associated with its presence in HIV-infected patients under highly active antiretroviral therapy (HAART) and to assess the changes of bone mineral density (BMD) in a population followed prospectively. METHOD:BMD was ass...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/4X0H-UVMJ-BHYW-CPFB

    authors： Fernández-Rivera J,García R,Lozano F,Macías J,García-García JA,Mira JA,Corzo JE,Gómez-Mateos J,Rueda A,Sánchez-Burson J,Pineda JA

    更新日期：2003-09-01 00:00:00

  • Antiretroviral treatment regimen outcomes among HIV-infected prisoners.

    abstract：BACKGROUND:Despite the high prevalence of HIV in correctional settings, the duration of therapy and response to various highly active antiretroviral therapy (HAART) regimens in this setting is unknown. METHOD:Using a retrospective cohort study (1997-2002) of HIV-infected prisoners in Connecticut that linked demographi...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct0804-205

    authors： Springer SA,Friedland GH,Doros G,Pesanti E,Altice FL

    更新日期：2007-07-01 00:00:00

  • A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

    abstract：BACKGROUND:A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. METHODS:A prospective, open-label pilot simplification study of once-daily lopinavir/...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/hct1304-179

    authors： Cooper C,la Porte C,Tossonian H,Sampalis J,Ackad N,Conway B

    更新日期：2012-07-01 00:00:00

  • Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.

    abstract：:Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid ...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,评审

    doi：10.1310/7bwp-0x7f-nxna-qrnp

    authors： Holguín A,Soriano V

    更新日期：2002-09-01 00:00:00

  • Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV.

    abstract：OBJECTIVE:The efficacy of Product R, a nontoxic peptide-nucleic acid, was tested in 43 HIV-infected adults naïve to antiretroviral therapy. METHOD:Patients were randomized to receive Product R (21 patients) or placebo (22 patients). Dosage was two 1 mL subcutaneous injections daily on days 1-14, followed by 1 mL daily...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1310/N34A-653T-ABF5-8Q1R

    authors： Levett PN,Hirschman SZ,Roach TC,Broome H,Alexander RJ,Fraser HS

    更新日期：2002-07-01 00:00:00

  • Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study.

    abstract：BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,多中心研究

    doi：10.1310/4nb4-1gx6-4xvk-pbgl

    authors： Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

    更新日期：2003-07-01 00:00:00

  • Update on HIV lipodystrophy.

    abstract：:When prescribed appropriately and taken adherently, antiretroviral therapy can consistently and durably suppress HIV replication, potentially translating into years of near normal health for HIV-infected persons. However, presently available antiretrovirals are associated with a cluster of physical and metabolic sympt...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,评审

    doi：10.1310/XP75-7VJ5-HML2-YF1W

    authors： Kravcik S

    更新日期：2004-05-01 00:00:00

  • Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.

    abstract：PURPOSE:This retrospective study investigates the effect of prior nucleoside (nucleoside reverse transcriptase inhibitor [NRTI]) experience on 2-year virologic response to an initial protease inhibitor-highly active antiretroviral therapy (PI-HAART) regimen. METHOD:152 patients who started a PI (excluding saquinavir h...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/W17C-5DBH-D90E-17CG

    authors： Kazanjian P,Tashima K,Hollander T,Kaul D

    更新日期：2001-05-01 00:00:00

  • Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.

    abstract：BACKGROUND:Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients. METHODS:Diagnostic study to determine immune response against the H1N1v com...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1404-175

    authors： Bickel M,Lassmann C,Wieters I,Doerr HW,Herrmann E,Wicker S,Brodt HR,Stephan C,Allwinn R,Jung O

    更新日期：2013-07-01 00:00:00

  • Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

    abstract：PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/HAG3-8YA5-UDQC-36NX

    authors： Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

    更新日期：2005-03-01 00:00:00

  • A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

    abstract：OBJECTIVE:To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue. METHODS:Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Gen...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,meta分析

    doi：10.1310/hct1101-39

    authors： Raboud JM,Diong C,Carr A,Grinspoon S,Mulligan K,Sutinen J,Rozenbaum W,Cavalcanti RB,Wand H,Costagliola D,Walmsley S,Glitazone and Lipoatrophy Meta-Analysis Working Group.

    更新日期：2010-01-01 00:00:00

  • Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy.

    abstract：BACKGROUND:The best method for assessment of functional status in human immunodeficiency virus type 1 (HIV-1) infected persons is unknown. OBJECTIVE:We hypothesized that 3 instruments to assess frailty or disability in elderly populations would perform similarly in HIV-1-infected persons. METHODS:HIV-infected subject...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1306-324

    authors： Erlandson KM,Allshouse AA,Jankowski CM,Duong S,Mawhinney S,Kohrt WM,Campbell TB

    更新日期：2012-11-01 00:00:00

  • Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

    abstract：OBJECTIVE:To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily. DESIGN:Prospective, single-center study. METHOD:The patient database of the department of infectious diseases was screened for patients who had failed at lea...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/RFT5-7N0M-8C5G-0TL2

    authors： Arvieux C,Tattevin P,Souala FM,Jaccard P,Ruffault A,Bentué-Ferrer D,Tribut O,Chapplain JM,Dupont M,Bouvier C,Michelet C

    更新日期：2002-03-01 00:00:00

  • Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?

    abstract：PURPOSE:Proven clinical efficacy of protease-sparing regimens (PSR) has been shown. Concerns exist about broad applicability of these regimens in advanced naïve patients. Recent reports have associated a rise in liver enzymes with nevi rapine; however, no data exist with efavirenz. METHOD:17 consecutive antiretroviral...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/2V0B-HDWC-AGWR-H56M

    authors： Corales RB,Shrestha NK,Taege AJ,Isada CM,Rehm SJ,Schmitt SK,Gordon SM,Mawhorter SD

    更新日期：2001-01-01 00:00:00

  • Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.

    abstract：OBJECTIVES:Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequat...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1080/15284336.2016.1184827

    authors： Kim CJ,Walmsley SL,Raboud JM,Kovacs C,Coburn B,Rousseau R,Reinhard R,Rosenes R,Kaul R

    更新日期：2016-07-01 00:00:00

  • Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.

    abstract：OBJECTIVES:Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. DESIGN:To assess the anti-inflammatory effects of statins in HIV-infected patients, because very limited data are av...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1501-1

    authors： Calza L,Vanino E,Salvadori C,Manfredi R,Colangeli V,Cascavilla A,Di Bari MA,Motta R,Viale P

    更新日期：2014-01-01 00:00:00